210 related articles for article (PubMed ID: 34931365)
1. Dupilumab for atopic dermatitis.
Pediatr Dermatol; 2021 Nov; 38(6):1559-1560. PubMed ID: 34931365
[No Abstract] [Full Text] [Related]
2. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response.
Nettis E; Ferrucci SM; Pellacani G; Di Leo E; Argenziano G; Foti C; Rongioletti F; Patruno C; Ortoncelli M; Macchia L; Tavecchio S; Bonzano L; Di Bona D; Calabrese G; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e896-e898. PubMed ID: 34310749
[No Abstract] [Full Text] [Related]
3. Atopic dermatitis, dupilumab and cancers: a case series.
Siliquini N; Giura MT; Viola R; Ribero S; Panzone M; Dapavo P; Fierro MT; Ortoncelli M; Quaglino P
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e651-e652. PubMed ID: 33797094
[No Abstract] [Full Text] [Related]
4. Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
Waldman RA; DeWane ME; Sloan SB; King B; Grant-Kels JM
J Am Acad Dermatol; 2021 Sep; 85(3):735-736. PubMed ID: 31325553
[No Abstract] [Full Text] [Related]
5. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.
Marcant P; Balayé P; Merhi R; Jendoubi F; Nosbaum A; Raison-Peyron N; Du-Thanh A; Lasek A; Ferrier le Bouedec MC; Tetart F; Valois A; Barbarot S; Soria A; Jachiet M; Staumont-Sallé D;
J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):e394-e396. PubMed ID: 33594731
[No Abstract] [Full Text] [Related]
7. Success of dupilumab as a monotherapy in an adult patient affected by severe uncontrolled asthma and atopic dermatitis.
Tolino E; Proietti I; Sarni A; Bernardini N; Mambrin A; Balduzzi V; Maddalena P; Marchesiello A; Michelini S; Volpe S; Skroza N; Potenza C
Dermatol Ther; 2021 Jan; 34(1):e14596. PubMed ID: 33244860
[No Abstract] [Full Text] [Related]
8. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Peccianti C; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavo SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Stingeni L; Caruso C; Argenziano G;
J Dermatolog Treat; 2022 Mar; 33(2):1146-1149. PubMed ID: 32436765
[No Abstract] [Full Text] [Related]
9. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
10. Eczema herpeticum and herpetic keratitis after the loading dose of dupilumab in a worsening atopic dermatitis: causality?
Benaglia C; Aromolo IF; Giacalone S; Morini N; Zussino M; Di Benedetto A; Marzano AV; Ferrucci SM
Int J Dermatol; 2023 Dec; 62(12):1547-1548. PubMed ID: 37715466
[No Abstract] [Full Text] [Related]
11. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
13. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
14. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
15. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
Deleuran M; Marcoux D; Bruin-Weller MS; Irvine AD; Baselga E; Ahn K; Castro AP; Bansal A; Chao J; Bégo-Le-Bagousse G; Rossi AB
Acta Derm Venereol; 2021 Jul; 101(7):adv00504. PubMed ID: 34043020
[No Abstract] [Full Text] [Related]
17. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
18. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
[No Abstract] [Full Text] [Related]
19. Dupilumab for the Treatment of Atopic Dermatitis.
Ferreira S; Torres T
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
